A small randomized clinical trial in China involving mild COVID-19 patients treated with darunavir/cobicistat for five days on top of interferon-alpha 2b inhalation or interferon alpha 2b inhalation alone did not demonstrate any increase in the proportion of negative conversion compared to standard of care alone [123]. Here, IFNA2 is linked to COVID-19.